|
Scott L. Nyberg, M.D., Ph.D.
![]() Scott L. Nyberg, M.D., Ph.D.
Location:
Minnesota
SummaryThe bioartificial liver is an important therapy developed to stabilize patients experiencing liver failure. The BAL functions outside of the patient?s body, similar to hemodialysis in the treatment of kidney failure. However, the BAL is a ?hybrid? extracorporeal device in that it contains hepatocytes, most commonly of porcine or human origin, as a biological source of liver function. My research interests are focused on the development of a multidisciplinary bioartificial liver program to improve the treatment of liver failure and support the clinical liver transplant program. A multidisciplinary liver support team exists at Mayo and this team has participated in a phase III clinical trial of the HepatAssist BAL system. We have also developed our own BAL system based on spheroid technology and expect that these studies will lead to an improved device for clinical treatment of acute liver failure. Recent publicationsEducation
Fellowship
–
Solid Organ Transplantation
Chief Resident
Residency
–
General Surgery
Doctor of Philosophy
–
Biomedical Engineering
M.D.
B.S.
–
Chemical Engineering
|
Legal restrictions and terms of use applicable to this site
Use of this site signifies your agreement to the terms of use
Copyright © 2008 Mayo Foundation for Medical Education and Research.